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Abstract
Background: Shared decision-making (SDM) is a patient-centred approach in which clinicians and patients work
side-by-side to decide together on the best course of action for each patient’s particular situation. Six key elements
of SDM can be distinguished: situation diagnosis, choice awareness, option clarification, discussion of harms and
benefits, deliberation of patient preferences and making the decision. Decision aids (DAs) are tools that facilitate
SDM. The impact of DAs for chronic illnesses on SDM, clinical and patient reported outcomes remains uncertain.
Methods: We will perform a systematic review aiming to describe (a) which SDM elements are incorporated in
DAs for adult patients with chronic conditions and (b) the effects of DA use on SDM, clinical and patient reported
outcomes. This manuscript reports on the protocol for this systematic review. The following databases will be
searched for relevant articles: PubMed, Embase, Web of Science, CINAHL and PsycINFO, from their inception to
October 2016. We will ascertain ongoing research by querying experts and searching trial registries. To enhance
feasibility, we will limit the review to randomized controlled trials (RCTs) including patients with chronic
cardiovascular and/or respiratory diseases and/or diabetes. SDM elements incorporated in DAs, DA effects and DA
itself will be described.
Discussion: This study will characterize DAs for chronic illness and will provide an overview of their effects on
SDM, clinical and patient reported outcomes. We anticipate this review will bring to light knowledge gaps and
inform further research into the design and use of DAs for patients with chronic conditions.
Systematic review registration: PROSPERO registration number: CRD42016050320.
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Background
Shared decision-making (SDM) is a patient-centred ap-
proach in which clinicians and patients work together to
choose the best course of action for each patient’s particu-
lar situation [1]. Although most SDM research has been
conducted in the context of one-time decisions, SDM is
also relevant in decisions that can be reconsidered over
time, as is often the case in the self-management of
chronic conditions [2].
In general, a distinction can be made between six key
elements of SDM: situation diagnosis, choice awareness,
option clarification, discussion of harms and benefits,
deliberation of patient preferences and making the deci-
sion [1–4]. The opening of an SDM interaction involves
a diagnostic conversation (situation diagnosis) [1]. This
conversation focuses first on understanding the patient’s
situation and establishing what aspects require action [1, 4].
When more than one reasonable alternative option is avail-
able, the clinician should clearly indicate this and highlight
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that the preferences of the patient are important in deciding
on the course of action (choice awareness) [3]. Subse-
quently, the clinician and the patient discuss how each op-
tion fits and accommodates within each patient’s situation
(option clarification, discussion of harms and benefits and
deliberation of patient preferences). Finally, the clinician
and patient reach a decision [2, 4]. When fruitful, SDM re-
sults in a course of action that is needed, wanted and more
likely to be implemented [5, 6]. SDM may also help facili-
tate a stronger clinician-patient relationship and shared un-
derstanding of treatment of patients’ health and life goals
[7, 8]. To date, the effects of SDM on clinical outcomes
have been found to vary across studies [9–11].
To facilitate SDM, decision aids (DAs) have been de-
veloped for use by clinicians and patients, either in prep-
aration for or during the clinical encounter [12, 13] and
are designed to help them participate in decisions that
involve weighing the harms and benefits of different
treatment options [12]. DAs can increase patient know-
ledge, reduce decisional conflict, help patients choose an
option that is congruent with their values, reduce the
proportion of patients remaining undecided and/or who
play a passive role in the decision-making process and
can have a positive effect on patient-clinician communi-
cation [12, 14–17]. These findings, however, mostly re-
late to one-time decisions. Whether the DAs designed
for use in chronic conditions actually support the key
elements of SDM and improve outcomes is unclear.
The aims of this review therefore are to (1) describe
which SDM elements are present in DAs for patients
with chronic conditions, including cardiovascular dis-
eases, chronic respiratory diseases and/or diabetes, (2)
determine the effects of these DAs compared to usual
care or active controls (i.e. alternative interventions such
as patient education) on frequently studied SDM outcomes
(i.e. decisional conflict, knowledge, patient participation in
decision-making, treatment decision (preference), treat-
ment satisfaction, decision satisfaction, conversation satis-
faction, risk expectations and perceptions and consultation
time) and (3) determine the effects of these DAs on clinical
outcomes (i.e. lipid levels, blood pressure, smoking status,
(maximal) oxygen uptake, glycaemic control, body mass
index (BMI), adherence and achieving treatment goals)
and patient reported outcomes (i.e. quality of life, perceived
health status, emotional distress and self-efficacy) com-
pared to usual care or active controls.
Since collecting data on DAs available for all chronic
illnesses is unfeasible, we selected those chronic condi-
tions the World Health Organization recognizes as most
prevalent [18–20] and are most likely to require self-
management. The selected SDM, clinical- and patient-
reported outcomes are considered by the authors as
most relevant for the selected chronic conditions. We
hypothesize that DAs that cover multiple elements of
SDM will be more likely to have positive effects on SDM
(process) outcomes, as well as on patient reported out-
comes. For clinical outcomes, we have no reason to
hypothesize a consistent response.
Methods
Study design
This protocol adheres to the Preferred Reporting Items
for Systematic Review and Meta-analysis Protocols
(PRISMA-P) (see “Additional file 1 PRISMA-P check-
list.pdf” for the PRISMA-P checklist) [21].
Eligibility criteria
Type of studies
Articles will be selected if they report on randomized
controlled trials (RCTs) comparing the use of DAs for
one or more of the selected chronic conditions to usual
care and/or active controls. There will be no limit to the
study setting and time frame.
Type of participants
Studies enrolling adult (18 years or older) patients with
a diagnosis of a chronic condition defined by the World
Health Organization as main types [18–20] and requiring
self-management: cardiovascular diseases (e.g. coronary
heart disease, cerebrovascular disease, peripheral arterial
disease, rheumatic heart disease, congenital heart disease,
deep vein thrombosis, pulmonary embolism, myocardial
infarction and stroke), chronic respiratory diseases (e.g.
chronic obstructive pulmonary disease (COPD), asthma,
occupational lung diseases and pulmonary hypertension)
and/or diabetes (types 1 and 2) will be included.
Type of interventions
Any DA designed to help clinicians and/or adult patients
in shared decision-making will be included [12].
Type of outcome measures
SDM outcomes (i.e. decisional conflict, knowledge, patient
participation in decision-making, treatment decision
(preference), treatment satisfaction, decision satisfaction,
conversation satisfaction, risk expectations and percep-
tions and consultation time) will be assessed. Clinical out-
comes (i.e. lipid levels (LDL cholesterol, HDL cholesterol,
total cholesterol, triglycerides), blood pressure, smoking
status, (maximal) oxygen uptake, glycaemic control, body
mass index (BMI), adherence and achieving treatment
goals) and patient reported outcomes (i.e. quality of life,
perceived health status, emotional distress (anxiety,
illness-related distress) and self-efficacy) will also be ex-
tracted. There will be no restrictions based on measure-
ment methods.
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Information sources and search strategy
With the help of an expert librarian (LJS), we will design
and conduct a search strategy to find eligible articles on
RCTs in the following databases from inception to
October 2016: PubMed, Embase, Web of Science,
CINAHL (through EBSCO), PsycINFO (through EBSCO)
and Cochrane Library (see Additional file 2 Search
strategy.pdf for the search strategy). The design and con-
duction of this search strategy will be finished around Oc-
tober 2016. There will be no restrictions based on
language, year of publication or year of development of
the DAs. Around September 2017, the initial electronic
search strategy will be carried out a second time for ar-
ticles published between October 2016 and September
2017. This second electronic search strategy will be
supplemented by screening the reference lists from in-
cluded studies to identify potentially eligible studies
that may have been missed. In addition, ongoing re-
search will be traced by contacting experts in the field
and searches in databases for ongoing research (including:
http://isrctn.com, http://narcis.nl, http://trialregister.nl
and http://www.clinicaltrials.gov). If published before the
publication date of our systematic review (submission will
take place around December 2017), ongoing studies will
be included when data extraction for included studies is
completed (September 2017). We will contact field experts
to inquire about ongoing RCTs fulfilling our eligibility cri-
teria. These contacts will be established through e-mail,
Facebook, LinkedIn and other media or face-to-face con-
tact in February 2017. Author contact will be documented
by name of sender, date of contact and full content of e-
mail, Facebook message, LinkedIn message or other way
of contact. If multiple articles are available on one RCT,
all will be included (articles on interim analyses as well).
Search activities will be documented by filling in a table
including search term(s), information source, date of
coverage and total number of publications found.
Data management
All search results will be uploaded into Covidence for
automatic de-duplication (October 2016). Covidence will
be used for both abstract (November and December
2016) and full-text screening (January 2017 until March
2017). The total number of results before and after de-
duplication will be documented per database.
Selection process
Prior to abstract screening, eligibility criteria will be iter-
ated for clarity to ensure comprehension by reviewers.
Two reviewers will independently assess whether the ab-
stracts of articles meet eligibility criteria. Since some
outcomes may not be reported in the abstract (e.g. due
to word restrictions) but are in the full-text article, out-
comes will not be considered during the abstract
screening phase. When reviewers disagree about in-
cluding an abstract, the full text will be considered.
Abstract screening will take place from November to
December 2016.
Following the screening of titles and abstracts, corre-
sponding full-text articles will again be assessed inde-
pendently by two reviewers. After a pilot with 20
included full-texts, discrepancies will be discussed and
instructions and/or criteria adapted if needed. Disagree-
ments and this phase will be resolved by consensus or
arbitration by a third reviewer. Reasons for non-
eligibility will be documented by the reviewers. Further-
more, agreement between reviewers (yes/no) and deci-
sion following consensus agreement (including date of
consensus) will be captured for every reference. Chance-
adjusted inter-rater agreement for full-text screening will be
estimated using the Kappa statistic [22]. Full-text screening
will take place from January 2017 to March 2017.
During both title/abstract and full-text screening, the
total number of titles/abstracts or full-texts before and
after screening will be documented, as well as the num-
ber of excluded titles/abstracts or full-texts (including
reasons for exclusion of full-texts).
Data collection process
Two reviewers will independently collect data for all eli-
gible full-text articles on RCTs. Data will not be col-
lected for articles on interim analyses, if articles on the
same RCT based on the total follow-up period are avail-
able (we will include those with the total follow-up). Re-
sults for all time spans (follow-up measurements/time
intervals) will be captured. If one DA is tested in mul-
tiple trials, all will be included. A data extraction form,
including information about publication, DA characteris-
tics, SDM elements and effectiveness, will be designed
and pilot tested before use (see Additional file 3 Data to
extract.pdf for the data extraction form). After extracting
data from five full-text reports (or all articles when less
than five full-text articles will be eligible), the noted dif-
ferences between reviewers will be discussed in order to
get optimal calibration for data extraction. If necessary
or desired, the extraction form will be adapted based on
feedback from the reviewers to improve usability and en-
sure completeness. Similar to article selection, two or
more reviewers will independently extract data. Dis-
agreements will be resolved by consensus. If consensus
on data extraction between the two parties cannot be
reached, a third reviewer will arbitrate.
A recent study showed that health information tools
developed and tested online hardly remain available and
accessible [23]. Therefore, all corresponding authors of
included studies will be contacted through e-mail to as-
sess whether the DA is currently available and used in
practice. Non-responders will be sent a reminder email
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after 2 weeks. If the second attempt is unsuccessful,
other authors will be contacted. If none of the authors
responds, we will contact the corresponding author (or
other authors) by phone. Every author contact will be
documented by name of the sender, date of contact and
full content of e-mail contact or a summary of telephone
contact. See Additional file 3 for the characteristics per
DA to be retrieved and entered in the data extraction
form. Data collection will take place around August 2017.
Missing data
If data presented in the studies is unclear, missing or
presented in a form that is either un-extractable or
difficult to reliably extract, we will request data from the
authors following the same author contact protocol de-
scribed above. As above, author contact will be docu-
mented by date and full content of e-mail contact.
Risk of bias in individual studies
Risk of bias will be assessed in individual studies using
the Cochrane Collaboration’s tool for assessing RCTs
risk of bias. This tool takes into consideration six do-
mains: (1) sequence generation, (2) allocation conceal-
ment, (3) blinding of participants and personnel, (4)
blinding of outcome assessment, (5) incomplete out-
come data, (6) selective outcome reporting and (7) other
biases. Two reviewers will independently assess the risk
of bias at all domains for every RCT [24]. Criteria for
judgement per domain are to be found in Chapter 8 of
the Cochrane Handbook for Systematic Reviews of
Interventions [25]. Disagreement will again be resolved
by consensus or if not possible, by arbitration of a third
reviewer. Risk of bias in individual studies will enable a
critical view on interpretation of DA effects found and
will be assessed around September 2017.
Outcomes and data synthesis
We will describe the RCTs included in our review, as
well as the DAs that are tested in these studies. This in-
cludes the SDM elements incorporated in DAs, the ef-
fects of DAs on SDM outcomes (i.e. decisional conflict,
knowledge, patient participation in decision-making,
treatment decision (preference), treatment satisfaction,
decision satisfaction, conversation satisfaction, risk ex-
pectations and perceptions, consultation time), clinical
outcomes (i.e. lipid levels (LDL cholesterol, HDL choles-
terol, total cholesterol, triglycerides), blood pressure,
smoking status, (maximal) oxygen uptake, glycaemic con-
trol, body mass index (BMI), adherence and achieving
treatment goals) and patient reported outcomes (i.e.
quality of life, perceived health status, emotional
distress (anxiety, illness-related distress) self-efficacy).
For continuous outcomes mean (change) differences
between intervention and control group, together with
p values and 95% confidence intervals (95% CIs), will
be extracted. Regarding dichotomous outcomes, both
risk ratios (RRs) and odds ratios (ORs) with 95% CIs
will be extracted or calculated if needed and possible.
Furthermore, elements of SDM incorporated in DAs,
risk of bias per RCT and DA itself will be described.
Since heterogeneous populations and outcomes will be
synthesized and much heterogeneity in time spans/in-
tervals is expected, performing a meta-analysis will be
difficult and perhaps not as useful. Therefore, in the
likely event that conducting random-effects meta-
analyses of the effects of these DAs on outcomes proves
unwise, we will summarize the results narratively. Data
will be synthesized around October 2017.
Discussion
This is an overview of chronic care DAs developed and
tested in RCTs, SDM elements they support and their
effects on clinical and patient reported outcomes. The
insights produced in it will help inform further research
aimed at developing, testing and successfully implementing
future DAs in clinical practice for patients with chronic
conditions.
Our proposed review also has potential limitations.
Other than duplicate assessment and clear eligibility cri-
teria, we do not have safeguards in place to prevent a
biased set of studies to be included. Also, since we are
interested in the efficacy of DAs, we will limit our search
strategy to RCTs as these have the most valid experi-
mental design of research [26]. This may exclude (well
designed and developed) DAs that have not (yet) been
tested in trials. Finally, we limit our search strategy to
the most prevalent cardiovascular diseases, chronic re-
spiratory diseases and diabetes [18–20], an incomplete
list of chronic diseases. Learnings from this review may
help further study the utility of DAs in the SDM process
in less prevalent chronic conditions.
This review will provide a broad overview of DAs
available for patients with cardiovascular, chronic re-
spiratory diseases and diabetes, as well as SDM elements
they incorporate and their effects on a broad range of
outcomes. It may bring to light useful information to a
variety of stakeholders including funding agencies,
policy-makers, researchers, clinicians and patients with
chronic conditions with the objective of delivering kind
and careful care to patients with chronic conditions.
Additional files
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